{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-032514","form_type":"8-K","ticker":null,"cik":"0001559356","company_name":"Biostax Corp.","filed_at":"2023-09-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.293107+00:00","generated_at":"2026-06-10T19:02:57.365208+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"CEO Kelly Wilson and President Robert Wilson resign; Noreen Griffin appointed CEO","bullets":["Robert Wilson resigned as President on July 25, 2023; no dispute cited.","Kelly Wilson resigned as CEO on July 25, 2023; appointed President same day.","Noreen Griffin named CEO under consulting agreement; monthly fee $20,834, deferred until $1M funding threshold with 8.5% interest.","Griffin, age 70, previously VP of company and former CEO; family ties to both Wilson executives.","Kelly Wilson's compensation continues under prior consulting agreement dated November 1, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-032514","json":"https://secwatch.observer/filing/0001493152-23-032514.json","markdown":"https://secwatch.observer/filing/0001493152-23-032514.md","text":"https://secwatch.observer/filing/0001493152-23-032514.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1559356/000149315223032514/0001493152-23-032514-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1559356/000149315223032514/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T19:02:57.365208+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4290935cdf","claim":"Robert Wilson resigned as President at Biostax Corp..","evidence_excerpt":"On July 25, 2023, Robert Wilson, President and director of Immune Therapeutics, Inc. d/b/a Biostax Corp. (the “Company”), delivered a letter of resignation to the Company, pursuant to which Mr. Wilson resigned as President of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1559356/000149315223032514/0001493152-23-032514-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"48007433ac","claim":"Kelly Wilson resigned as Chief Executive Officer at Biostax Corp..","evidence_excerpt":"On July 25, 2023, Kelly Wilson, Chief Executive Officer and Chief Operating Officer of Company, delivered a letter of resignation to the Company, pursuant to which Ms. Wilson resigned as Chief Executive Officer of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1559356/000149315223032514/0001493152-23-032514-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"93c01558b1","claim":"Noreen Griffin was appointed as Chief Executive Officer at Biostax Corp..","evidence_excerpt":"On July 25, 2023, the Board of the Company appointed Noreen Griffin as Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1559356/000149315223032514/0001493152-23-032514-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}